Boston Scientific Corp. co-founders John Abele and Peter Nicholas unloaded millions of dollars worth of their stakes in the company in March alone.
It’s part of their effort to salvage the Natick-based medical device leviathan’s stock price, which fell from about $45 per share five years ago to less than $9, according to The Boston Globe.
Add to that the failure of its Taxus Express drug-eluting stent and the disastrous, $27 billion buyout Guidant Corp. (which added $10 billion in debt and thousands of safety recalls in 2006).